How I treat frontline transplantation-eligible multiple myeloma
Author:
- 12 May 2022
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 139 (19) , 2882-2888
Abstract
High-dose melphalan supported by autologous transplantation has been the standard of care for eligible patients with newly diagnosed multiple myeloma (MM) for >25 years. Several randomized clinical trials have recently reaffirmed the strong position of transplantation in the era of proteasome inhibitors and immunomodulatory drugs combinations, demonstrating a significant reduction of progression or death in comparison with strategies without transplantation. Immunotherapy is currently changing the paradigm of MM management, and daratumumab is the first-in-class human monoclonal antibody targeting CD38 approved in the setting of newly diagnosed MM. Quadruplets have become the new standard in transplantation programs, but outcomes remain heterogeneous, with various response depth and duration. The development of sensitive and specific tools for disease prognostication allows the consideration of strategies adaptive to dynamic risk. This review discusses the different options available for the treatment of transplantation-eligible patients with MM in frontline setting.Keywords
This publication has 39 references indexed in Scilit:
- International Myeloma Working Group updated criteria for the diagnosis of multiple myelomaThe Lancet Oncology, 2014
- Autologous Transplantation and Maintenance Therapy in Multiple MyelomaNew England Journal of Medicine, 2014
- Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patientsLeukemia, 2013
- Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 TrialJournal of Clinical Oncology, 2012
- Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myelomaBlood, 2012
- Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple MyelomaNew England Journal of Medicine, 2012
- Lenalidomide after Stem-Cell Transplantation for Multiple MyelomaNew England Journal of Medicine, 2012
- Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17pBlood, 2012
- Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myelomaBlood, 2011
- Bortezomib Plus Dexamethasone Is Superior to Vincristine Plus Doxorubicin Plus Dexamethasone As Induction Treatment Prior to Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: Results of the IFM 2005-01 Phase III TrialJournal of Clinical Oncology, 2010